Mamta Parikh, MD,MS

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Pfizer
    Topic:
    Consulting
    Date added:
    07/31/2024
    Date updated:
    07/31/2024
    Relationship end date:
    08/31/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Bristol Myers Squibb
    Topic:
    Advisory Board
    Date added:
    07/31/2024
    Date updated:
    07/31/2024
    Relationship end date:
    04/19/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Sanofi Aventis
    Topic:
    Advisory Board
    Date added:
    07/31/2024
    Date updated:
    07/31/2024
    Relationship end date:
    06/20/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Karyopharm
    Topic:
    Research Support
    Date added:
    07/31/2024
    Date updated:
    07/31/2024
    Relationship end date:
    01/01/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Gilead
    Topic:
    Research Support
    Date added:
    07/31/2024
    Date updated:
    07/31/2024
Return to Northern California Hematology Oncology Conference: A Tumor Board Case-Based Approach to the Latest Breakthroughs